TABLE 1.

Data on inhibitor classes, inhibitory mechanisms, and current clinical trial status.

	Inhibitors	Type of inhibitor	Type of inhibition	Phase trial status	Applicability	Reference
1	Avibactam	DBO	Reversible	Phase III a	GNO	Lahiri et al. (2013)
2	Clavulanic acid	β-Lactam	Irreversible	Phase III a	BGNP	Sydor and Challis (2012)
3	Captopril	Metallo-β-lactam inhibitor	Reversible	Phase II	BGNP	Zhao et al. (2021)
4	Durlobactam	DBO	Reversible	Phase III	GNO	Shapiro et al. (2021)
5	Enmetazobactam	Cyclic boronate inhibitor	Irreversible	Phase III	GNO	Lang et al. (2022)
6	ETX0282	DBO	Reversible	Phase I	GNO	Lahiri et al. (2013)
7	Nacubactam	Non-β-lactam	Reversible	Phase I	GNO	Lang et al. (2021)
8	Relebactam	Non-β-lactam	Irreversible	Phase III a	GNO	Stachyra et al. (2010)
9	Sulbactam	β-Lactam	Irreversible	Phase IV a	BGNP	Carcione et al. (2021)
10	Tazobactam	β-Lactam	Irreversible	Phase IV a	BGNP	Tooke et al. (2019)
11	Taniborbactam	Cyclic boronate inhibitor	Reversible	Phase I	GNO	Lui et al. (2020)
12	Vaborbactam	Cyclic boronate inhibitor	Reversible	Phase I a	GNO	Tsivkovski et al. (2020)
13	WCK-4234	DBO	Reversible	Preclinical trials	GNO	Papp-Wallace et al. (2018a)
14	Xeruborbactam	Cyclic boronate inhibitor	Reversible	Phase I	BGNP	Lomovskaya et al. (2021)
15	Zidebactam	DBO	Reversible	Phase III	BGNP	Rajavel et al. (2021)

^a Currently used clinically.

GNO, gram-negative organisms; BGNP, both gram-negative and positive organisms.